Bon usage du sorafénib chez les patients pris en charge pour un carcinome hépatocellulaire ou un cancer du rein

O. Rosmorduc; C. Chevreau; P. Dielenseger; S. Ederhy; F. Goldwasser; J. D. Grange; L. Mortier; M. E. Neidhardt-Berard; C. Robert; F. Scotté; J. F. Seitz

doi:10.1016/j.gcb.2009.12.004

Bon usage du sorafénib chez les patients pris en charge pour un carcinome hépatocellulaire ou un cancer du rein

O. Rosmorduc, C. Chevreau, P. Dielenseger, S. Ederhy, F. Goldwasser, J. D. Grange, L. Mortier, M. E. Neidhardt-Berard, C. Robert, F. Scotté, J. F. Seitz

Résultats de recherche: Contribution à un journal › Brève enquête › Revue par des pairs

2 Citations (Scopus)

Résumé

Therapeutic approaches of cancers have been recently improved by the development of targeted therapies. Amongst these new drugs, some anti-angiogenic molecules have been approved by either the EMEA or the Food and Drug Administration. Sorafenib, one of these inhibitors of angiogenesis, has been established as the standard of care for advanced hepatocellular and renal carcinoma. This paper reviews the safety profile of sorafenib and presents guidelines for the prevention and the treatment of the main side effects associated with this molecule.

Titre traduit de la contribution	Guidelines for treatment of hepatocellular or renal carcinoma with sorafenib
langue originale	Français
Pages (de - à)	161-167
Nombre de pages	7
journal	Gastroenterologie Clinique et Biologique
Volume	34
Numéro de publication	3
Les DOIs	https://doi.org/10.1016/j.gcb.2009.12.004
état	Publié - 1 mars 2010

Accès au document

10.1016/j.gcb.2009.12.004

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Rosmorduc, O., Chevreau, C., Dielenseger, P., Ederhy, S., Goldwasser, F., Grange, J. D., Mortier, L., Neidhardt-Berard, M. E., Robert, C., Scotté, F., & Seitz, J. F. (2010). Bon usage du sorafénib chez les patients pris en charge pour un carcinome hépatocellulaire ou un cancer du rein. Gastroenterologie Clinique et Biologique, 34(3), 161-167. https://doi.org/10.1016/j.gcb.2009.12.004

@article{7fd7b69eeec44b59b7bb2ba4dd7d4c4e,

title = "Bon usage du soraf{\'e}nib chez les patients pris en charge pour un carcinome h{\'e}patocellulaire ou un cancer du rein",

abstract = "Therapeutic approaches of cancers have been recently improved by the development of targeted therapies. Amongst these new drugs, some anti-angiogenic molecules have been approved by either the EMEA or the Food and Drug Administration. Sorafenib, one of these inhibitors of angiogenesis, has been established as the standard of care for advanced hepatocellular and renal carcinoma. This paper reviews the safety profile of sorafenib and presents guidelines for the prevention and the treatment of the main side effects associated with this molecule.",

author = "O. Rosmorduc and C. Chevreau and P. Dielenseger and S. Ederhy and F. Goldwasser and Grange, {J. D.} and L. Mortier and Neidhardt-Berard, {M. E.} and C. Robert and F. Scott{\'e} and Seitz, {J. F.}",

year = "2010",

month = mar,

day = "1",

doi = "10.1016/j.gcb.2009.12.004",

language = "Fran{\c c}ais",

volume = "34",

pages = "161--167",

journal = "Gastroenterologie Clinique et Biologique",

issn = "0399-8320",

number = "3",

}

Rosmorduc, O, Chevreau, C, Dielenseger, P, Ederhy, S, Goldwasser, F, Grange, JD, Mortier, L, Neidhardt-Berard, ME, Robert, C, Scotté, F & Seitz, JF 2010, 'Bon usage du sorafénib chez les patients pris en charge pour un carcinome hépatocellulaire ou un cancer du rein', Gastroenterologie Clinique et Biologique, VOL. 34, Numéro 3, p. 161-167. https://doi.org/10.1016/j.gcb.2009.12.004

TY - JOUR

T1 - Bon usage du sorafénib chez les patients pris en charge pour un carcinome hépatocellulaire ou un cancer du rein

AU - Rosmorduc, O.

AU - Chevreau, C.

AU - Dielenseger, P.

AU - Ederhy, S.

AU - Goldwasser, F.

AU - Grange, J. D.

AU - Mortier, L.

AU - Neidhardt-Berard, M. E.

AU - Robert, C.

AU - Scotté, F.

AU - Seitz, J. F.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Therapeutic approaches of cancers have been recently improved by the development of targeted therapies. Amongst these new drugs, some anti-angiogenic molecules have been approved by either the EMEA or the Food and Drug Administration. Sorafenib, one of these inhibitors of angiogenesis, has been established as the standard of care for advanced hepatocellular and renal carcinoma. This paper reviews the safety profile of sorafenib and presents guidelines for the prevention and the treatment of the main side effects associated with this molecule.

AB - Therapeutic approaches of cancers have been recently improved by the development of targeted therapies. Amongst these new drugs, some anti-angiogenic molecules have been approved by either the EMEA or the Food and Drug Administration. Sorafenib, one of these inhibitors of angiogenesis, has been established as the standard of care for advanced hepatocellular and renal carcinoma. This paper reviews the safety profile of sorafenib and presents guidelines for the prevention and the treatment of the main side effects associated with this molecule.

UR - http://www.scopus.com/inward/record.url?scp=77950922353&partnerID=8YFLogxK

U2 - 10.1016/j.gcb.2009.12.004

DO - 10.1016/j.gcb.2009.12.004

M3 - Brève enquête

C2 - 20181452

AN - SCOPUS:77950922353

SN - 0399-8320

VL - 34

SP - 161

EP - 167

JO - Gastroenterologie Clinique et Biologique

JF - Gastroenterologie Clinique et Biologique

IS - 3

ER -